Ultrahuman’s racing partnership is about more

Alamar and Nightingale will hunt rare, low-level

A late-breaking slot in Boston will bring fresh

Tiny Health announced two new features, Microbiom

Revive Health and FitOn Health have combined to f

Six-month University of Surrey RCT sees better e

L-Nutra Health launches a clinician-led metaboli

A Phase 1 study of MNA-001, which targets TREM2,

Emory researchers say a 10-protein plasma signat

Eliquent Life Sciences has joined ExoCordOA, a €13 million, five-year Horizon Europe consortium coordinated by Exogenus Therapeutics that aims to advance extracellular vesicle-enriched secretome therapies toward clinical use, initially targeting osteoarthritis. The program intends to support Phase I and II development of Exogenus’s lead candidate, EXO-101, as a potential disease-modifying treatment, while addressing scientific, manufacturing, quality-control, and regulatory challenges that affect the translation of secretome-based medicines. Eliquent will provide regulatory development expertise to the ten-organization consortium, which includes biotechnology, manufacturing, clinical and academic partners such as Lonza, Anthony Nolan, Utrecht University and Maastricht University Medical Center+. The consortium also plans to develop more standardized approaches, robust analytical and potency-assessment methods and a clearer regulatory pathway for future secretome therapies. According to the consortium announcement, osteoarthritis affects about 8% of the global population, and no disease-modifying osteoarthritis drugs are currently approved. The company claims its integrated expertise spans regulatory affairs, quality and compliance, and pharmacovigilance and safety. The post Eliquent joins €13m Horizon Europe consortium appeared first on Longevity.Technology.

Superpower has launched Superpower Peptides, offe

Fractyl’s Revita hit its six-month goal in a s

Latus Bio‘s Nature Communications paper models

Twelve abstracts head to The Liver Meeting, incl

Why the next breakthroughs in healthy aging may

LifeVantage released results of a two-part in vit

Exogenus Therapeutics is coordinating ExoCordOA,

Fractyl has expanded its U.S.

John Hancock and MIT AgeLab’s second index fin

The preclinical results for RV-8451, an oral GLP

NeuroXT’s NEXT-Cue pairs brain MRI with cognit

Prenuvo and UT Dallas researchers found links be

Five-year research program will examine how gene

Decades founder Eva Novak on why the blue zone i

Digbi Health announced ASRA, a precision biology-

Biogen will present new data across its Alzheimer

Eisai will present new five-year data for lecanem

Sironax announced that three abstracts on its SAR

A Biograph study using AI on routine heart CT sc

iBio says its Activin E antibody kept weight los

Fitnescity Health opens its 1,000-plus imaging l

United Therapeutics will test treprostinil SMI i

Voyager Therapeutics announced two poster present

Omre released independent laboratory analysis ver

Research by The Business Research Company project

Avaí Bio announced the publication of a peer-rev

The Hanover biomarker company will grow its lab

The Boston company says the deal more than doubl

Mission Therapeutics has begun a 36-patient Phas

After 12 weeks, members of Omada’s GLP-1 Care

Organoids are full of cells that shouldn’t be

VeriSIM Life is participating in an Advanced Rese

Haut.

Sironax is about halfway to its enrollment target

XellSmart’s off-the-shelf XS411 lifted motor s

Rapalogix reports firmer, more elastic skin in a

Cognito Therapeutics and the state’s Life Scie

Fractyl Health’s Revita beat a sham procedure

Fractyl Health’s Revita beat a sham procedure

Swiss fertility heavyweight bets on stem-cell-de